Portfolio of Canceropole CLARA Proof of Concept projects

1. CLARA TRANSFER:
FROM RESEARCH TO APPLICATION IN ONCOLOGY
A PUBLIC ‐ PRIVATE PARTNERSHIP BETWEEN
RESEARCHERS, CLINICIANS AND ENTREPRENEURS

3. CLARA TRANSFER: A UNIQUE PROGRAM TO SUPPORT
THE TRANSFER OF CANCER RESEARCH FINDINGS
At the critical stage of cancer research when academic financing and expertise become insufficient,
CLARA Transfer brings in funding and specialized networks to perform the Proof of Concept studies
that will convince partners to proceed with clinical and industrial development.
3

4. SUPORTING PROMISING AND INNOVATIVE PROJECTS
TOWARDS INDUSTRIAL AND CLINICAL TRANSFER
Clearly Focused Projects
• Pre‐clinical and/or clinical Proof of Concept
• Industrial and Clinical transfer
Industrial and Clinical transfer
Project with Solid Foundations
• p yp p
Clear and obtainable candidate or prototype to be tested and developed
• Established Intellectual Property
• Clear transfer and development strategy, led by the partner company
Complementary Partners and leadership in CLARA's region
• Academic and clinical partners
• Start‐up or Innovative company with a clear development plans in the Region
p p y p p g
• Open to partners beyond CLARA boarders (funding to be determined)
High medical and industrial interest for oncology
• Therapeutics, Devices, Diagnostics, Technologies…
4

5. CLARA TRANSFER:
PERSONALIZED ASSISTANCE AND DEVELOPMENT SUPPORT
Personalized Significant & Flexible
Assistance Financing*
Large
Dedicated Academic and Industrial
Network of
Team Senior Clinical Costs Costs
Partners &
Development Contractors CLARA Industrial
Co ac o s
Experts Transfer
T f Partner
P t
After Proof of Concept:
Aft P f f C t
• Pursuit of project by the partner company
• Royalties for academic and clinical partners
• Commitment from the company to reinvest in CLARA R&D
Commitment from the company to reinvest in CLARA R&D
* Average budget per project: €1.2M including €600K from the Cancéropôle CLARA
5

6. KEY NUMBERS AND RESULTS OF CLARA TRANSFER
CLARA
30 projects supported since 2005
• 20 ongoing projects
• 7 successful Proof of Concept projects completed
7 successful Proof of Concept projects
Budget: €36M
g 10 Advanced Projects
10 Advanced Projects
• Public Authorities & European
• 1 on the market
ERDF Funds (€11M)
• 5 in clinical development
• Partnering Companies (€25M)
• 4 validated at pre‐clinical
4 validated
level
22 Innovative Companies 70+ Partners Involved
• 7 Start‐ups • 43 Academics
• 7 companies raised €90M
p • 7 Clinical Centers
7 Clinical
• 1 foreign company subsidiary • 22 Companies
establishment (Japan)
6

7. CLARA TRANSFER:
SEVEN PROOF OF CONCEPT PROJECTS COMPLETED
Clinical Proof of Concept:
• ViKY, Mini‐Robot for Solid Cancers Laparoscopic Surgery (First success story in 2009)
• High‐Intensity Focused Ultrasound Device for the Treatment of Liver Metastases from
Colorectal Cancer (Preclinical POC and AFSSAPS agreement in 2009, Clinical phase IIa ongoing)
Preclinical Proof of Concept:
• Photosensitive Nanoparticles for Glioblastoma Treatment (2009)
• Lung Cancer Therapeutic Targeting with TLR3 Receptor Agonists (2009)
• Mini‐Invasive Biopsy Tool for Non‐Lesional Cellular and Proteic Footprints of Tumoral Nodes
(2010)
• Hybrid Nanoprobes as Imaging Agents to Trace Cells in the Course of Cellular Therapy
Protocoles in Melanoma (2011)
• Fluorescence Imaging Device for Peroperative Detection of Tumor Margins and Metastases in
Sarcomas (2012)
7

8. CLARA TRANSFER ‐ ADVANCED PROOF OF CONCEPT PROJECTS
MARKETED OR IN CLINICAL DEVELOPMENT
Acronym and Title of Cancer Types Academic & Clinical Partner Budget Stage of See
Project Partners Company Develop‐ Page
ment
ViKY: Light endoscopic robot Prostate, liver, ‐ TIMC Lab (CNRS 5525, UJF), EndoControl 2007‐2009: €425K Marketed 13
for laparoscopic cancer pancreas, colon, Grenoble Medical, €212K CLARA (Europe, USA)
surgery lung Grenoble €213K Endocontrol
HIFU: High Intensity Focused Liver metastasis ‐ LabTAU, Inserm, Lyon EDAP TMS, 2007‐2012: €1.1M Phase IIb 14
Ultrasound device for the
l dd f h from colorectal
f l l ‐ Léon Bérard Cancer Center,
é é d Lyon €535K CLARA ongoing
treatment of liver metastases cancer Experimental Surgery Institute, €565K EDAP TMS
from colorectal cancer Inserm, Lyon
Lymphos'1: Low T‐Cell Metastatic Breast ‐Cancer Research Center, Lyon ImmunID 2008‐2012: €850K Clinical 15
Receptors Diversity (Divpenia)
p y( p ) and Lung
g ‐Léon Bérard Cancer Center,
, Technologies,
g , €425K CLARA
€425K CLARA p p
prospective
Combined with Lymphopenia cancers Lyon Grenoble €425K ImmunID studies ongoing
predicts poor Overall Survival
in Metastatic Breast Cancer
Patients
Synfrizz: Innovative R di
S fi I ti Radio‐ Synovialo‐
S i l ‐ Lé Bé d C
Léon Bérard Cancer Center,
C t OncoTherapy
O Th 2010‐2014: €6.3M
2010 2014 €6 3M Clinical h
Cli i l phase I
I 16
immunotherapy for synovialo‐ sarcoma Lyon Science, Lyon €751K CLARA ongoing
sarcoma treatment, targeting €5.6M OncoTherapy
FZD10 functionnal and specific Science
antigen
Enki‐HEH: New endoscopic Superficial ‐ Lyon University Hospital NESTIS, Lyon 2011‐2012: €350K Clinical phase I 17
resection device for colorectal, gastric (HCL) €140K CLARA ongoing
superficial colorectal, gastric and esophageal €206K NESTIS
and esophageal neoplasms neoplasms
GeniusVac‐Mel4: Therapeutic
GeniusVac Mel4: Therapeutic Melanoma ‐ Joseph Fourier University
Joseph Fourier University, French
French 2011‐2015: €1.7M
2011 2015: €1 7M Clinical Trial
Trial 18
vaccine based on dendritic French National Blood Service, National Blood €698K CLARA Authorization
cells to treat metastatic INSERM, University Hospital Service (EFS), €1M EFS Application
melanoma Center, Grenoble Grenoble ongoing
8

9. CLARA TRANSFER ‐ COMPLETED PRECLINICAL PROOF OF CONCEPT PROJECTS
TO BE TRANSLATED INTO CLINICAL TRIALS
Acronym and Title of Cancer Types Academic & Clinical Partner Budget Stage of See
Project Partners Company Develop‐ Page
ment
GanglioTool: Mini‐invasive Lymphoma, ‐ CEA/LETI, Grenoble CEA, Grenoble 2008‐2010: €380K ‐ Preclinical POC 9
biopsy tool for non lesional Metastatic ‐ CEA/Clinatec, Grenoble €250 K CLARA completed
cellular and proteic footprint mediastinal teaching hospital, GIN €130K CEA ‐ Clinical trial
of tumoral nodes nodes ‐ Lyon Civil Hospitals dossier in
‐ Saint‐Etienne University development
d l
Hospital
Claraft: Fluorescence imaging Sarcoma ‐ Léon Bérard Cancer Fluoptics, 2010‐2012: 1M€ ‐ Preclinical POC 20
device for peroperative Center, Lyon Grenoble €508K CLARA completed
detect o o tu o a g s
detection of tumor margins ‐Albert Bonniot Institute,
be t o ot st tute, €510K Fluoptics
€510K Fluoptics ‐ Clinical trial
C ca t a
and metastases in sarcomas Inserm, Joseph Fourier dossier in
University, Grenoble development
‐Veterinary School
VetAgroSup, Lyon
NSH: Hybrid nanoprobes as
NSH H b id b Melanoma
M l ‐L
Lyon Civil Hospitals, UCBL
Ci il H it l UCBL Nano‐H, Saint‐
N H S i t 2007‐2011: €615K
2007 2011 €615K Preclinical POC
P li i l POC 21
imaging agents to trace cells Quentin €307K CLARA completed
in the course of cellular Fallavier €308K Nano‐H
therapy protocoles in
melanoma
9

10. CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTS
THERAPEUTIC MOLECULES
Acronym and Title of Cancer Academic & Clinical Partner Budget Stage of See
Project Types Partners Company Develop‐ Page
ment
CANCERDRUG: Preclinical Vascularized solid ‐ Grenoble Neurosciences Ecrins 2010‐2012: €1M Preclinical POC 22
validation of a novel vascular tumors Institute, Inserm, University of Therapeutics, €628K CLARA ongoing
disrupting agent (VDA) targeting Grenoble Grenoble €407K Ecrins
PP1 ‐ Curie Institute, Paris Therapeutics
IPROMAH: Humanized therapeutic Non‐hodgkin's Lyon Civil Hospitals, Lyon iDD Biotech, 2009‐2012: €1M Preclinical POC 23
monoclonal antibodies against CD5 lymphomas University, Lyon Cancer Dardilly €354K CLARA ongoing
and CD19 for non‐hodgkin's Research Center €646K IDD Biotech
lymphomas
LANTHARAD: Targeted hybrid
LANTHARAD: Targeted hybrid Melanoma,
Melanoma ‐ Lyon Civil Hospitals UCBL
Lyon Civil Hospitals, UCBL, Nano‐H,
Nano‐H Saint‐ 2009‐2012: €615K Preclinical POC
POC 24
radiosensitizer nanoparticles for Chondro‐ LPCML, Lyon Quentin €404K CLARA ongoing
radiotherapy of melanoma and sarcoma, Head ‐ Inserm U990, Clermont‐ Fallavier €211K Nano‐H
chondrosarcoma and Neck, Ferrand
Gliosarcoma
LIPOBAK: Bak protein
LIPOBAK: Bak protein associated Glioblastoma ‐TheRex Laboratory Joseph
TheRex Laboratory, Joseph Synthélis,
Synthélis 2010‐2013: €430K
2010 2013: €430K Preclinical POC
POC 25
proteoliposomes for glioblastoma Fourier University (UJF), Grenoble €228K CLARA ongoing
treatment Grenoble €206K Synthélis
‐ Neurobiology and Transgenesis
Laboratory, Angers
10

11. CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTS
THERAPEUTIC MOLECULES
Acronym and Title of Cancer Academic & Clinical Partner Budget Stage of See
Project Types Partners Company Develop‐ Page
ment
NETRIS: Drug candidates based on Lung, Metastatic Lyon Cancer Research Center, Netris Pharma, 2008‐2012: €1.6M Preclinical POC 26
Dependence Receptors concept breast cancer Léon Bérard Cancer Center, Lyon Lyon €800K CLARA ongoing
inhibiting Netrin‐1/DCC‐UNC5 in €800K Netris Pharma
lung cancer and NT‐3/TrkC in
metastatic breast cancer
metastatic breast cancer
THERA 8: Targeting cell surface Colo‐rectal Lyon Cancer Research Center IDD biotech, 2011‐2014: € 713K Preclinical POC 27
CK8 for the development of cancer (CCR) (CRCL) Dardilly € 354K CLARA ongoing
therapeutic antibodies for € 359K IDD biotech
colorectal cancers
TRT/PETMEL: Development of Metastatic UMR 990 Inserm, Auvergne Cyclopharma 2009‐2013: €830K Preclinical POC 28
heteroaromatic halogenated melanoma University, Clermont‐Ferrand Laboratories, €416K CLARA ongoing
molecules for either PET or SPECT Clermont‐ €414K Cyclopharma
imaging and Targeted Radionuclide Ferrand
Therapy of metastatic melanoma
Therapy of metastatic melanoma
11

12. CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTS
SURGICAL DEVICES
Acronym and Title of Cancer Types Academic & Clinical Partner Budget Stage of See
Project Partners Company Develop‐ Page
ment
Doc Calipso: Robot navigation for Small solid tumors ‐ Lyon 1 Claude Bernard ADEPT, Annecy 2010 to 2013: €1.3M Preclinical POC 29
small tumor focal therapy University, Lyon Civil Hospitals €627K CLARA ongoing
€629K ADEPT
Hépatofluo: Indocyanine Green Liver cancer and ‐ Léon Bérard Cancer Center, Fluoptics, 2011‐2014: €1M Preclinical POC 30
as a near‐infrared fluorescent metastases Lyon Grenoble €498K CLARA ongoing
contrast agent and mini‐camera €498K Fluoptics
Fluobeam® for image‐guided
liver surgery
Nano Eno: Nanoencapsulated Solid tumors ‐ CEA, Grenoble & Orsay Advanced 2010‐2013: €700K Preclinical POC 31
nuclear/optical imaging probe ‐ Veterinary School Accelerator €426K CLARA ongoing
VetAgroSup, Lyon Applications €269K AAA
(AAA), Saint‐
Genis Pouilly
Uroclip: Automatic uretro‐vesical Prostate cancer ‐ Veterinary School Anastom Surgical, 2011‐2013: €400K Preclinical POC 32
anastomosis system in prostate VetAgroSup, Lyon Lyon €278K CLARA ongoing
cancer €118K Anastom‐
Surgical
12

13. Surgical Device Prostate, Liver, Pancreas, Colon, Lung… Clinical POC Completed
Marketed (USA, Europe)
VIKY: ENDOSCOPIC ROBOT FOR LAPAROSCOPIC CANCER SURGERY (€ 2 )
(€425K)
CONCEPT MAIN RESULTS
• A light and intelligent robotic endoscope holder for • 3 patents
laparoscopic surgery, with either voice or foot control • European CE mark and AFSSAPS agreement (2009)
by surgeon • Clinical validation in 300 laparoscopic surgical procedures,
• Added Value: Light, easy, low cost; reduces personnel including complex cancer surgeries (prostate, liver,
needs, freeing staff for alternative operating room pancreas, colon, lung…), proved that ViKY is at least as
tasks and reducing the need for personnel allowing
personnel, secure and efficient as human surgeon assistants with a
one of them to perform other tasks in the operating positive influence on the quality of the surgery.
room
ACADEMIC/CLINICAL PARTNERS PROSPECTS
• Further collaboration and development of new innovative
p
• J TROCCAZ TIMC Lab (CNRS 5525 UJF Grenoble)
J. TROCCAZ, TIMC Lab (CNRS 5525, UJF, Grenoble)
solutions for robotic laparoscopic surgery
• 4 clinical cancer centers
• Commercialization at the international level
PARTNER COMPANY: EndoControl Medical
• Spin‐off of the TIMC Lab, founded in 2006 in Grenoble
to design, develop and commercialize innovative
robotic solutions for laparoscopic surgery
• EndoControl raised €4M equity and is marketing its
products in the USA and Europe
• Contact: Clément VIDAL (CEO),
www.endocontrol‐medical.com
13
Maj

14. Surgical Device Liver Metastasis from Colorectal Cancer Clinical POC Ongoing
HIFU: HIGH‐INTENSITY FOCUSED ULTRASOUND DEVICE FOR THE TREATMENT OF
LIVER METASTASES FROM COLORECTAL CANCER (€1,1 M)
CONCEPT MAIN RESULTS
• A High‐Intensity Focused Ultrasound (HIFU) device for the • Patented technology (Inserm‐Edap, 2005)
treatment of non resectable liver metastases as a
non‐resectable • Preclinical proof of concept with CLARA support (
l l f f h (2007‐
complementary treatment to surgery 2009)
• Added Value: 10 to 20% of patients are suitable for curative • Ethical committee and AFSSAPS agreement to start clinical
surgery. HIFU may be used as a complementary tool to studies (2009)
surgery in order to increase the rate of treatment performed
with a curative intent
intent. • Safety and feasibility validated in a Phase I/IIa clinical
y y /
study on 15 patients (2010‐2011)
HIFU advantages: Treatment is non‐invasive for the liver,
independent from hepatic blood flow (allowing the PROSPECTS
treatment of metastases that are currently unresectable),
rapid and without limit in terms of size. Real‐time • Phase IIb efficacy clinical study ongoing on 20 patients with
ultrasound imaging is used during treatment and offers a CLARA support (2012)
reliable visualization of the therapeutic intervention. • Multicenter clinical trials, CE approval
• Ongoing developments: application to pancreatic
ACADEMIC/CLINICAL PARTNERS
tumors, liver resection assisted by HIFU and
• D. MELODELIMA, J‐Y. CHAPELON, (Lab of Therapeutic extracorporeal treatment
p
Applications of Ultrasound, INSERM & UCBL1, Lyon)
• Pr M. RIVOIRE (Léon Bérard Cancer Center, Experimental
Surgery Institute, Inserm, Lyon)
PARTNER COMPANY: EDAP TMS
PARTNER COMPANY: EDAP TMS
• Leader of therapeutic ultrasound, founded in 1979 in Lyon
(Nasdaq : EDAP)
• Contact : Emmanuel BLANC (CTO), www.edap‐tms.com
14
Maj

15. Immuno‐Monitoring Metastatic Breast and Lung Cancers Clinical POC Ongoing
LYMPHOS1: Low TCR Diversity (Divpenia) Combined with Lymphopenia predicts poor Overall
y( p ) y p p p p
Survival in Metastatic Breast Cancer Patients (€850 K)
CONCEPT MAIN RESULTS 14/04/12
• The “Number & Diversity of Lymphocytes" (NDL) score • Patented technology (CEA, ImmunID Technologies, Léon
based on combined measurement of lymphocyte count and Bérard Cancer C
Bé d C Center))
immune TCR diversity measured by the ImmunTraCkeR
platform to detect immuno‐deficiency in patients with • Lymphopenia or Lympho‐divpenia (NDL score 1) patients
either metastatic breast or lung cancer undergoing have poor overall survival in metastatic Breast Cancer
chemotherapy cases
• Added Value: Lymphopenia is observed in 20% of untreated
metastatic b
t t ti breast cancer patients and i associated with an
t ti t d is i t d ith • Patients cohorts can be stratified to adapt chemical
increased risk of early death partly due to chemotherapy treatments like Avastin, Taxol or Taxoter
immunotoxicity: this test will allow the selection of patients
to adapt their treatment; it will also allow the development PROSPECTS
of innovation in immunotherapy and targeted therapies. • Prospective validation studies ongoing for metastatic
Breast and Lung Cancer Patients (2012)
g ( )
• Clinical Assay Elypse 7 to measure the efficiency of IL7
ACADEMIC/CLINICAL PARTNERS treatment in metastatic breast cancer patients
• Pr J‐Y. BLAY (Léon Bérard Cancer Center, Lyon)
• C. CAUX, Ch. CAUX (Lyon Cancer Research Center)
PARTNER COMPANY: ImmunID Technologies
cyte count
• Emerging diagnostic company founded in 2005 as a spin‐off Low Risk
of the CEA, specialized in combinatorial immune repertoire
ga/L)
analysis (services and kit commercialization)
y ( )
(Gig
Lymphoc
• ImmunID Technologies raised €6M from public and venture
capital sources, and is searching for new public and/or
private partners High Risk
• Contact: Nicolas PASQUAL (CEO), www.immunid.com
hTRB VJ combinatorial
bi t i l
diversity (%)
15
Maj

16. Radio‐Immunotherapy Synovialo‐Sarcoma Clinical POC Ongoing
SYNFRIZZ: INNOVATIVE RADIO‐IMMUNOTHERAPY FOR SYNOVIALO‐SARCOMA TREATMENT
TARGETING FZD10, A TUMOR SPECIFIC ANTIGEN (€6.3M) màj 04.07.12
CONCEPT MAIN RESULTS
• GMP‐antibody and radiolabeling process patented (OTS)
• Radio‐immunotherapy using a “first in man/first in class”
• Preclinical POC achieved (OTS)
humanized monoclonal antibody targeting a tumor • Antibody production process and radiolabeling validated
specific antigen, Frizzled‐10 (FZD10), radiolabeled with 90 • A first‐in‐man, first‐in‐class, randomized phase I open‐label,
Ytrium two‐step, multicenter clinical trial authorized by AFSSAPS in
October 2011
• Added Value: Orphan disease with no efficient systemic
• Trial kick‐off in Léon Bérard Cancer Center and first patient
treatment in late stage cases inclusion in January 2012
• 4 patients recruited (June 2012)
ACADEMIC/CLINICAL PARTNERS PROSPECTS
• Pr J‐Y. BLAY, Dr D. PEROL, Dr P. CASSIER, Dr I. RAY‐COQUARD
• Phase I clinical trial extension to Bordeaux (Institut
(Léon Bérard Cancer Center, Lyon)
Bergonié) and Villejuif (Gustave Roussy Institute) Cancer
Centers
• Phase II clinical trial protocol design to start in 2014
PARTNER COMPANY: OncoTherapy Science (OTS)
• The approach will be extended to other indications:
• J
Japanese bi
biotech which set up a F
h hi h French R&D subsidiary
h b idi Gastric and colorectal cancers
company in Lyon, in 2010
• Contact: Simon BACONNIER (CSO, OTS France),
www.oncotherapy.co.jp/eng/
16
Maj

17. Colorectal, gastric and esophageal
Medical Device Clinical POC Ongoing
cancers
ENKI‐HEH: NEW ENDOSCOPIC RESECTION DEVICE FOR SUPERFICIAL COLORECTAL, GASTRIC AND
,
ESOPHAGEAL NEOPLASMS (€350K)
CONCEPT MAIN RESULTS
• High pressure pulsed water jet system for endoscopic • Patent (Nestis, 2010)
submucosal resection
b l • CE Mark (September 2011)
• Added Value: Easy to use, faster, low risk of perforation, • Preclinical Proof of concept validated on pigs’ colon (2012)
not reserved to expert surgeons • ANSM agreement (April 2012)
• Clinical Proof of Concept on colorectal, esophageal and
stomachal cancers (ongoing since June 2012)
ACADEMIC / CLINICAL PARTNERS
• Pr. T. PONCHON (Lyon Civil Hospitals)
PROSPECTS
• FDA agreement (2012)
• Multicentric clinical study (Paris and Marseille)
DEVELOPMENT PARTNER: Nestis • Establishment of Reference Centers in Europe for the use of
• Created in 2010 (Lyon) Enki HEH technology in tumor resections
• Develop and market high pressure pulsed water jet
resection device
• Contact: Dr. Christian PINSET (President)
Enki II device for endoscopic
Enki‐II device used for endoscopic
submucosal resection
17
Maj 25/09/2012

18. Cell Therapy Vaccine Melanoma Clinical POC Scheduled
GENIUSVAC‐MEL4: THERAPEUTIC VACCINE BASED ON DENDRITIC CELLS TO TREAT
METASTATIC MELANOMA (€1.7M)
CONCEPT MAIN RESULTS
• Innovative therapeutic vaccine based on allogeneic • Cell lines, methods patented (EFS)
plasmacytoïd d d i i cells l d d with 4 melanoma
l ïd dendritic ll loaded i h l • Preclinical POC achieved in 2010, in “humanized” murine
peptides (MelanA, Gp100, Tyr and Mage‐3) model and ex vivo with patients immune cells
• Added Value: Allogeneic approach, one cell line for • Ethical Committee agreement December 9, 2011 for clinical
several patients, simple scaling‐up, low cost production, trials
easy access treatment • Cli i l work plan and IMPD d i d i collaboration with
Clinical k l d designed in ll b ti ith
CLARA experts to obtain AFSSAPS approval for phase I clinical
ACADEMIC/CLINICAL PARTNERS trial (2012)
• J. PLUMAS (UJF‐EFS‐INSERM U823, Grenoble) • GMP production of melanoma peptides
• Pr. M‐T. LECCIA and Pr. J‐L BOSSON (University Hospital
M T. JL
Center, Grenoble) PROSPECTS
• GMP production of a Master Cell Bank (2012)
PARTNER COMPANY: • Phase I clinical trial: Kick‐off in 2012, to end in 2015
French National Blood Service (EFS)
( ) • POC in other therapeutic applications: Lung cancer, chronic
• EFS main activity is blood transfusion. In France, EFS is the viral pathologies such as Hepatitis B, virus‐induced cancer
leading supplier for human tissues and cells such as HPV+ cervical cancer …
• Involvement of the Cell Therapy Unit in Saint‐Ismier (near
Grenoble)
• Contact: Joël PLUMAS (Project Manager) or Laurence LE
TEXIER (TTO Director), www.dondusang.net
18
Maj

19. Diagnostic Device Lymphoma Preclinical POC Completed
Metastatic Mediastinal Nodes
GANGLIOTOOL: MINI‐INVASIVE BIOPSY TOOL FOR NON‐LESIONAL CELLULAR AND PROTEIC FOOTPRINT
OF TUMORAL NODES (€380K)
CONCEPT MAIN RESULTS
• A sampling device consisting of a hollow biopsy guide • 6 patents (CEA, Inserm, UJF)
with a lateral opening and a silicon chip with micro
micro‐ • Ex vivo validation on extracted human nodes
structures (pillars) with chemical surface modifications,
capturing biological molecules and cells after apposition • High quality validation of recovered micro samples by
on a tissue (fingerprint). cytological techniques
• Added Value: Quantitative and qualitative improvements • No toxicity of the modified surface detected in vitro
of sampling and increase of patients comfort during PROSPECTS
diagnosis and therapeutic monitoring of malignancies,
• Clinical proof of concept with a multicentric clinical trial on
particularly for lymphoma, metastatic mediastinal nodes glioblastoma patients as of 2012 (Pr F. Berger, CEA/Clinatec)
and tissue areas difficult to explore.
• Developments for other tumor locations (such as sarcoma,
ACADEMIC/CLINICAL PARTNERS
/ lung, li ) peri‐tumor tissues, neurodegenerative b i
l liver), i i d i brain,
• M‐L. COSNIER (CEA/LETI, Grenoble) endoscopy, intravascular explorations…
• Pr F. BERGER (CEA/Clinatec, Grenoble University Hospital, • Diversification and extension of the technology may support
GIN), Pr G. SALLES (Lyon Civil Hospitals), Pr M. COTTIER, Pr the creation of a start‐up.
J.M.
J M VERGNON and P O TIFFET (S i t Eti
d Pr O. (Saint‐Etienne U i
University
it
Hospital)
PARTNER COMPANY: CEA‐Leti
• CEA Laboratory based in Grenoble (MINATEC®) and
y ( )
dedicated to applied research and transfer for health
• Contact: Raymond CAMPAGNOLO (Program Manager)
www.leti.fr and Pr François BERGER (CLINATEC, GIN)
19
Maj

20. Imaging/Medical Device Sarcoma Preclinical POC Completed
CLARAFT: FLUORESCENCE IMAGING DEVICE FOR PEROPERATIVE DETECTION OF TUMOR MARGINS AND
METASTASIS IN SARCOMAS (€1M)
CONCEPT MAIN RESULTS
• A system to guide surgeons, combining a fluorescent • Instrumentation, imaging method (CEA, 2005, 2006, 2007)
probe targeting αvβ3 integrins (
b β (AngioStamp®) and a near
®) d and probe patented (Inserm/CNRS/UJF 2007)
d b d
IR camera, for tumor margins and metastases • Detection with millimeter accuracy of tumor margins and
peroperative detection lung metastases on rat osteosarcoma model and feline fibro
• Added Value: Technology compatible with surgical unit sarcoma, preGMP probe regulatory toxicology harmlessness
light, biodistribution specificity in a cats.
ACADEMIC/CLINICAL PARTNERS PROSPECTS
• A. DUTOUR (Léon Bérard Cancer Center, Lyon) • Multicentric Phase I/II clinical assay kick‐off (2012)
• J L COLL (Alb t B
J‐L. (Albert Bonniot I tit t I
i t Institute, Inserm, J
Joseph
h
Fourier University, Grenoble)
• Pr C. CAROZZO (VetAgroSup Veterinary School, Lyon)
PARTNER COMPANY: Fluoptics
PARTNER COMPANY Fl i
• CEA spin‐off created in 2009 in Grenoble: Development
and marketing of real time imaging systems to help
human surgery, based on fluorescent probes and a mini
camera
• Fluoptics raised a capital of €750K and is searching for
€750K,
industrial partners and/or investors. Fluoptics©
• Contact: Odile ALLARD (CEO), www.fluoptics.com
Near InfraRed camera developed by Fluoptics
20
Maj 25/09/2012

21. In vivo Imaging, Cell Therapy Melanoma Preclinical POC Completed
NSH: HYBRID NANOPROBES AS IMAGING AGENTS TO TRACE CELLS IN THE COURSE OF CELLULAR
THERAPY PROTOCOLS IN MELANOMA (€615K)
CONCEPT MAIN RESULTS
• Hybrid nanoparticles consisting of a magnetic core of • No functional alterations of labeled cells observed in vitro
lanthanide o ide coated b a pol silo ane shell as contrast
oxide by polysiloxane and in vivo
agents to label cells for MRI tracing during cellular therapy • In vivo detection and quantification with MR imaging of
protocols labeled cells in vivo after intraperitoneal and intravenous
• Added Value: To help assess cell therapy protocols that injection (mouse)
are rapidly developing in oncology but often show
p y p g gy • Capacity to produce nanoparticles of homogeneous size
disappointing clinical results; to help especially in the
choice of the administration route. PROSPECTS
• Clinical POC to be performed
ACADEMIC/CLINICAL COORDINATOR
/ • Relevant for different cell therapy protocols and more
extensively biotherapy (preventive and therapeutic
• Dr C. BILLOTEY (Lyon Civil Hospitals, UCBL) vaccines, transplantation...)
DEVELOPMENT PARTNER: Nano‐H
• N
Nanobiotech company f
bi h founded i 2004 as a spin‐off of
d d in i ff f
Lyon University to adapt, produce and commercialize
hybrid nanoparticles
• The project may finally be transferred to a company
involved in the therapeutic market t b f th
i l d i th th ti k t to be further
developed in collaboration with Nano‐H.
• Contact: Cédric LOUIS (CEO), www.nano‐h.com Magnetic Resonance Imaging allows to detect in vivo within
the spleen of a mouse (arrow) the labeled cells (right box) 24
hours after its intravenous injection
21
Maj

22. Small Chemical Molecule Vascular Solid Tumors Preclinical POC Ongoing
CANCERDRUG : PRECLINICAL VALIDATION OF A NOVEL VASCULAR DISRUPTING AGENT (VDA)
( )
TARGETING PP1 – PROTEIN PHOSPHATASE 1 (€1M)
CONCEPT MAIN RESULTS
• Development of D5 , a new chemical entity with VDA and • D5 series patented (University of Grenoble, Curie
anti‐mitotic
anti mitotic properties Institute, CNRS,
Institute CNRS 2010)
• Added Value: D5 specifically targets PP1, is active per os • Preclinical and clinical development planned (with the
and shows a good toxicology profile; contrary to most help of CLARA experts)
VDAs under development, D5 does not target tubulin and • Various human cancers evaluated in xenograft models to
is likely to be better tolerated by patients. identify those most sensitive to D5 (kidney, lung and
thyroïd); D5 compared to the best‐in‐class reference VDA
(CA4P); NMR allowed to predict/monitor D5 efficacy on
blood flow in tumors; different administration schedules
ACADEMIC/CLINICAL PARTNERS (iv, ip, per os) evaluated; unique dorsal chamber in vivo
model used to visualize/evaluate antivascular effects of
• C.REMY, B. VAN DER SANDEN, F. BERGER (Grenoble D5 and its analogues
Neurosciences Institute, Inserm, University of Grenoble )
, , y
• Curie Institute, UMR176, Grenoble PROSPECTS
• Regulatory toxicology and Phase I clinical trial (2013)
PARTNER COMPANY: Ecrins Therapeutics
• Biotech company, spin‐off of Grenoble Neurosciences
Institute, created in Grenoble in 2010. Ecrins Therapeutics is
a drug discovery company, which develops a pipeline of
chemical anti‐cancer drugs. Ecrins Therapeutics has an
exclusive licence on the D5 patent from the University of
Grenoble
• Ecrins Therapeutics is looking for industrial partners or
investors (€3M in 2012)
Tumoral necrosis after D5 treatment
• Contact: Andrei POPOV (CEO),www.ecrins‐therapeutics.com
22
Maj

23. Therapeutic MAb L.ymphomas Preclinical POC Ongoing
IPROMAH: IN VIVO PROOF OF CONCEPT OF HUMANIZED THERAPEUTIC MONOCLONAL ANTIBODIES
FOR NON‐HODGKIN’S LYMPHOMA AGAINST CD19 OR AGAINST CD5 (€1M)
CONCEPT MAIN RESULTS
• In vivo Proof of concept of humanized monoclonal • CD19: 2 patents, murine MAb selection and humanization,
antibodies targeting CD19 or CD5 for Non Hodgkin’s
Hodgkin s generation of humanized afucosylated anti CD19 MAb in
anti‐CD19 MAb,
Lymphoma in association with chemotherapy vitro MAb potency (CDC, ADCC, PCD) PK/PD, preliminary
• Added Value #1 : Development of “best in class” anti‐CD19 toxicity, in vivo mouse model efficacy in Rituxan refractory
MAb as an alternative to Rituxan relapse or refractory human lymphoma, bioprocess for industrial bioproduction
treatment • CD5: Murine MAb selection and humanization, in vitro MAb
• Added Value #2 : Development of anti‐CD5 MAb as an potency, in vivo mouse model available
alternative to adverse effects Alemtuzumab (CD52)
PROSPECTS
ACADEMIC / CLINICAL PARTNER • CD19 target: Completion of preclinical efficacy evaluation in
• Pr C. DUMONTET (Lyon Civil Hospitals, Lyon University, mono‐
mono and combino therapy in 2012 in vivo POC related to
combino‐therapy 2012,
Lyon Cancer Research Center) autoimmune diseases, USP and DSP development
• CD5 target: in vivo POC to be completed in 2012
PARTNER COMPANY: IDD Biotech
• iDD biotech is dedicated to the discovery and Anti CD19 MAb Efficacy in Rituximab Refractory Tumor Mouse
development of therapeutic monoclonal antibodies (MAb)
d l f h i l l ib di Model
Model
4000
for the treatment of cancer, autoimmune diseases, 3500 Untreated
inflammation or neurological disorders. Rituximab
olume (mm3)
3000
• With its proprietary hybridoma library and following MAb 2500
Anti CD19 MAb
engineering, iDD biotech develops the next generation of 2000
Tumor Vo
therapeutic antibodies.
h i ib di 1500
• iDD Biotech is actively looking for industrial and/or 1000
financial partners 500
IP injection (D26 D33 D40
0
• Contact : H. ROUQUETTE(CEO), C. DESROCHES (CSO) 26 36 46
c.vermotdesroches@idd biotech.com
c.vermotdesroches@idd‐biotech.com Number of days
23
Maj 25/09/2012

24. Melanoma, Chondrosarcoma,
Nanoparticles for Radiotherapy Preclinical POC Ongoing
Head and Neck, Gliosarcoma
,
LANTHARAD: TARGETED HYBRID RADIOSENSITIZER NANOPARTICLES FOR RADIOTHERAPY OF
MELANOMA AND CHONDROSARCOMA (€615K)
CONCEPT MAIN RESULTS
• Solid hybrid nanoparticles based on rare‐earth such as • Favorable biodistribution after iv injection of nanoparticles
Gadolinium, which specifically accumulates in tumors with renal elimination and no liver or lung accumulation
after direct intra‐tumoral administration or • In vitro and in vivo radiosensitizing effect on human
intravenous administration, by either passive or active radioresistant head and neck (SQ20B) xenograft model after
direct intra‐tumoral injection of nanoparticles
targeting properties (specific vectors), and which
amplify the effect of radiation (radiosensitizer).
p y ( ) • In vivo radiosensitizing effect (increase survival) in an
orthotopic i l t d model of murine gliosarcoma after i
th t i implanted d l f i li ft iv
• Added Value: Treatment of radioresistant tumors and injection
preservation of surrounding normal tissue • Specific chondrosarcoma targeting after iv injection of
functionalized nanoparticles
ACADEMIC / CLINICAL PARTNERS
• P M JANIER (L
Pr M. (Lyon Ci il H i l LPCML)
Civil Hospitals, PROSPECTS
• Pr C. RODRIGUEZ‐LAFRASSE (Lyon Civil Hospitals, • Clinical proof of concept of radiosensitizer nanoparticles on
UCBL), Pr J.M. CHEZAL (Inserm U990, Clermont‐ head and neck radioresistant patients upon intra‐tumoral
Ferrand), Pr O. TILLEMENT (LPCML, Lyon) direct administration
• Preclinical proof of concept of radiosensitizer targeting
PARTNER COMPANY: Nano‐H nanoparticles on a mouse chondrosarcoma model
• Nanobiotech company founded in 2004 as a spin‐off
of Lyon University to adapt, produce and
commercialize hybrid nanoparticles
• The project may finally be transferred to a new or an In vivo proteoglycanes targeting
with vectorized nanoparticles, in
existing company to be further developed. an orthotopic chondrosarcoma
• Contact: Cédric LOUIS (CEO), www.nano‐h.com rat model
24
Maj

25. Therapeutic Biomolecule Glioblastoma Preclinical POC Ongoing
LIPOBAK: B
LIPOBAK BAK PROTEIN‐ASSOC
O ASSOCIATED PROTEOLIPOSOMES FOR GLIOBLASTOMA TREATMENT (€430K)
O O OSO S O O S O
CONCEPT MAIN RESULTS
• LipoBak is a lipidic vector that includes a therapeutic • Production process, products and applications patented
protein (Bak) and a glioblastoma targeting peptide. (J‐L. LENORMAND, UJF, 2007). Targeting peptide
• Added Value: Strong apoptotic effect, specific tumor patented (Angers and McGill Universities, 2004)
targeting, no toxicity observed, versatile technology • Large‐scale production of membrane proteins, optimized
liposomal composition, innovative grafting of homing
peptide,
peptide preliminary results of efficacy demonstrated in
ACADEMIC/CLINICAL PARTNERS vitro and in vivo on glioblastoma models
• Pr J‐L. LENORMAND (TheRex Laboratory, Joseph
Fourier University (UJF), Grenoble) PROSPECTS
• Pr J. EYER (Neurobiology and Transgenesis Laboratory, • In vivo tests on xenograft murine brain
In vivo tests on xenograft murine brain tumor model
Angers)
• Non‐regulatory preclinical POC to be achieved in 2013
PARTNER COMPANY: Synthélis
• Grenoble based start‐up created in 2010, specialized in
membrane protein production
• Selection for the Franco‐American NETVA program
(New England Technology Venture Accelerator) to
develop Synthelis activity in the USA.
• Fund raising planned in 2012 to scale‐up the
production process to GMP grade
• Contact: Bruno TILLIER (CEO), www.synthelis.fr Bak protein‐associated proteoliposome
(Bak is represented in red)
25
Maj

26. Anticancer Drug Candidates Primary Lung, Metastatic Breast Cancer Preclinical POC Ongoing
NETRIS: DRUG CANDIDATES BASED ON DEPENDENCE RECEPTORS CONCEPT INHIBITING NETRIN‐1/
/
DCC‐UNC5 IN LUNG CANCER (€810K) AND NT‐3/TRKC IN METASTATIC BREAST CANCER (€800K)
CONCEPT MAIN RESULTS
• Drug candidates that trigger apoptosis targeting Netrin‐ • 2 patents, others in progress
1/DCC‐UNC5 in lung cancer and NT‐3/TrkC interaction in • Ongoing development of several types of molecules
metastatic breast cancer. showing promising preliminary results in terms of anti‐
• Added Value: A new class of anticancer drugs based on a tumoral effect, toxicity and pharmacodynamics‐
dependence receptor concept discovered by Pr P. MEHLEN pharmacokinetic parameters in animal models
(Lyon Cancer Research Center) Autocrine over‐expression
Center). over expression
of ligands of dependence receptors is found in several PROSPECTS
cancers and plays an important role in the control of • Preclinical proof of concept of 2 drug candidates (2012)
tumoral development. • Other potential cancer indications: Prostate, liver,
pancreas, colon, brain…
ACADEMIC / CLINICAL PARTNERS
Autocrine production of Netrin-1
• P. MEHLEN, J.G. DELCROS and S. TAUSZIG‐DELAMASURE
(Lyon Cancer Research Center, Léon Bérard Cancer Center,
Lyon)
PARTNER COMPANY: Netris Pharma
• Spin‐off of Pr MEHLEN’s Laboratory (Lyon Cancer Research
Center) founded in 2008 to develop therapeutic candidates
targeting dependence receptor in cancer
• Netris is searching for industrial and/or financial partners Negative signaling
APOPTOSIS
• Contact: Agnès BERNET (CEO) and Pascale NONY (COO), Positive signaling
proliferation, migration, survival
www.netrispharma.com
26
Maj

27. Therapeutic MAb Colorectal cancer Preclinical POC Ongoing
THERA 8: TARGETING CELL SURFACE CK8 FOR THE DEVELOPMENT OF THERAPEUTIC ANTIBODIES FOR
COLORECTAL CANCERS (€ 713K)
MAIN RESULTS
CONCEPT • PCT Patent on the utilization of proprietary antibodies
• Humanized monoclonal antibody targeting CK8 to reduce targeting CK8 to treat invasive and/or metastatic CRC
/
dissemination of colorectal cancers (CRC) cells (WO/2010/136536)
• Added Value: therapeutic MAb dedicated to the reduction • Encouraging preliminary in vivo data on the efficacy of
of the invasiveness of CRC cells combined with other mouse anti‐CK8 MAb
existing anti‐cancer treatments
g • Ongoing humanization of proprietary anti CK8 and
anti‐CK8
generation of new proprietary anti‐CK8 with several
ACADEMIC/CLINICAL PARTNERS immunization methods
• JJ DIAZ, MA ALBARET(Lyon Cancer Research Center(CRCL)) PROSPECTS
• Preclinical proof of concept of the anti‐invasive and/or anti‐
metastatic properties of the anti‐CK8 Mabs in mouse
PARTNER COMPANY: IDD Biotech models bearing human CRC xenografts (2014)
• iDD biotech is dedicated to the discovery and
• Better understanding of the role of CK8 and its isoforms in
development of therapeutic monoclonal antibodies
the invasive/metastatic process
(MAb) for the treatment of cancer, autoimmune diseases,
inflammation or neurological disorders. • C did t selection f clinical t
Candidate l ti for li i l transfer f
A fraction of the CK8 pool is
• With its proprietary hybridoma library and following MAb distributed in the
engineering, iDD biotech develops the next generation of intracellular compartment
therapeutic antibodies. within the intermediate
filament network (GFP‐CK8
• iDD Biotech is actively looking for industrial and/or labeled in ll ) h
l b l d i yellow) whereas
financial partners another fraction of this pool
• Contact: H. ROUQUETTE(CEO), C. DESROCHES (CSO) is localized at the external
surface of the cell (GFP‐CK8
c.vermotdesroches@idd‐biotech.com labeled in green and
endogeneous CK8 labeled in
red)
27
Maj 25/09/2012

28. Imaging, Radioimmmunotherapy Metastatic Melanoma Preclinical POC Ongoing
TRT/PET MEL: DEVELOPMENT OF HETEROAROMATIC HALOGENATED MOLECULES FOR EITHER
/
PET OR SPECT IMAGING AND TARGETED RADIONUCLIDE THERAPY OF METASTATIC MELANOMA (€830K)
CONCEPT MAIN RESULTS
• Heteroaromatic halogenated molecules for melanin • Patent on (radio)chemical entities and their (radio)synthesis
targeting radiolabelled with radioisotopes f PET (18F) or
d l b ll d h d for ) • Ongoing synthesis and preclinical evaluation of different
SPECT ( 123I) imaging and for targeted radionuclide therapy
candidates
(131I) of metastatic melanoma.
PROSPECTS
• Added Value: To perform (i) an early diagnosis and staging
of melanoma lesions by combining tracer specificity and • Pharmacomodulation and structure‐activity relationship
PET performance and (ii) a targeted radionuclide therapy studies in order to optimize metabolic and
with pre‐validated biodistribution pharmacokinetics profiles
• Candidate selection for clinical transfer (2013)
ACADEMIC/CLINICAL PARTNERS
• E MIOT‐NOIRAULT, J.M. CHEZAL (UMR 990 Inserm,
Auvergne University)
PARTNER COMPANY: Cyclopharma Laboratories
• Specialized European radiopharmaceutical company
founded in 2000 in Saint‐Beauzire, dedicated to the
development and production of radiopharmaceuticals for
nuclear medicine
• Contact: Pr Serge ASKIENAZY (Medical and One candidate selected : High tumor/background ratio, Early
and specific PET imaging of melanoma in mice, Targeted
Research Director), www.cyclopharma.fr Radionuclide Therapy after 131 I labeling: under evaluation in
melanoma bearing mice
28
PREFET DE LA REGION AUVERGNE
Maj

29. Surgical Device Small Solid Tumors Preclinical POC Ongoing
DOC CALIPSO: ROBOT
DOC CALIPSO RO O NAVIGATION FOR SMALL TUMOR FOC THERAPY (€1 3M)
G O O O OCAL (€1.3M)
CONCEPT MAIN RESULTS
• A robot with a tri‐dimensional navigation system guided • Robot patented (ADEPT)
by a patient’s implanted sensor, to position a focal • Robotic development ongoing: Compatibility success
treatment probe for radiofrequence, cryotherapy, high‐ between robot, operating table and instrumentation;
intensity focused ultrasound or laser neutral stand development ongoing, biocompatible
• Added Value: Standardization, 1/10 mm accuracy, respect sensors identified
of adjacent organs less agressive technique
organs, • Software development to correlate real time organ images
with RMI images, for probe positioning
• First robotic tests on soft tissues demonstrating the
ACADEMIC/CLINICAL PARTNERS positioning system accuracy
• Pr M. COLOMBEL (Lyon 1 Claude Bernard University,
Lyon Civil Hospitals) PROSPECTS
• Robot preclinical transfer to realize probe implantation
tests in dead organs, in a pig model and in a human body
PARTNER COMPANY: ADEPT • Preclinical POC expected in 2013
• Adept was created in 1983 in the USA, Adept
d d h d • ADEPT is searching for a partner
Technologie France in 1989, with R&D activity localized to industrialize Doc Calipso
in Annecy technology
• Leader in robot automated systems
• Contact: Bruno ADAM, www.adept‐technology.fr
DOC CALIPSO robot modeling
29
Maj 25/09/2012

30. Imaging/Medical Device Liver Cancer and Metastases Preclinical POC Ongoing
HEPATOFLUO: INDOCYANINE GREEN AS A NEAR‐INFRARED FLUORESCENT CONTRAST AGENT AND
MINI‐CAMERA FLUOBEAM® FOR IMAGE‐GUIDED LIVER SURGERY (€1M)
CONCEPT MAIN RESULTS
• Per‐operative imaging system, based on Indocyanine • Instrumentation and imaging method patented (CEA,
Green ((AMM) as a fl
) fluorescent marker, and a Fluobeam®
k d l b ® 2005, 2006, 2007))
mini‐camera • Preclinical POC ongoing: Added value demonstration of
• Added Value: Improvement of per‐operative quality Fluobeam® ‐ Indocyanine Green combination (to end in
imaging for image‐guided liver surgery, in order to 2012)
identify liver segments and tumorous lesions; technology
compatible with surgical unit light PROSPECTS
• Imaging camera optimization
• Clinical Trial submission and kick‐off (2013) in Léon Bérard
ACADEMIC/CLINICAL PARTNERS Cancer Center
• Dr P. PEYRAT (Léon Bérard Cancer Center, Lyon)
PARTNER COMPANY: Fluoptics
• CEA Spin‐off created in Grenoble in 2009: Development
and marketing of real time i
d k i f l i imaging systems to h l
i help
human surgery, based on fluorescent probes and a mini‐
camera
• Fluoptics raised a capital of €750K and is looking for
industrial partners and investors
• Contact: Odile ALLARD (CEO) www fluoptics com
(CEO), www.fluoptics.com
Fluobeam®
30
Maj

31. Imaging/Biomolecule Solid Tumors Preclinical POC Ongoing
NANO ENO: N O C S
NANO ENO NANOENCAPSULATED NUCLEAR/OPTICAL IMAGING PROBE (€700K)
C C G G O
CONCEPT MAIN RESULTS
• Lipidots™, hybrid lipidic nanovector carrying both a • Lipidots™ patented (CEA, 2007, 2008)
nuclear imaging agent (f PET or SPECT imaging) and an
l (for ) d • Bi‐modal nanocarrier optimization, physical and chemical
optical imaging agent properties characterization, quality control and in vitro tests
• Added Value: Lipidots™ are organic, non toxic and ongoing
biodegradable. The bi‐modality will allow pre‐operative
tumor identification and quantification, and per‐ per
operative surgery guidance. PROSPECTS
• In vivo tests on breast murine cancer and dog models
planned for 2012 and 2013
ACADEMIC/CLINICAL PARTNERS • Preclinical POC to end in 2013
• P BOISSEAU I TEXIER (CEA G
P. BOISSEAU, I. Grenoble), B TAVITIAN (CEA
bl ) B.
Orsay)
• F. PONCE (VetAgroSup Veterinary School , Lyon)
PARTNER COMPANY:
Advanced Accelerator Applications (AAA)
• AAA is a European pharmaceutical company set up in
2002; its main activity is to develop either therapeutic or
imaging molecules f patients’ targeted therapy. Th
i i l l for i ’ d h The
French company is located in Saint‐Genis Pouilly.
• Contact: Stefano BUONO (CEO), www.adacap.com
31
Maj 25/09/2012

32. Surgical Device Prostate Cancer Preclinical POC Ongoing
UROLINK: A O
UROLINK AUTOMATIC URETRO‐VESICAL ANASTOMOSIS SYSTEM IN PROSTATE CANCER (€400K)
C O V SC S O OS S S OS C
CONCEPT MAIN RESULTS
• UroLink is a mini‐invasive device designed to reconstruct • Device patented
the bladder neck and reconnect it to the urethra by
• Ex vivo feasibility POC on bladder and urethra
circular suturing (anastomosis) after a radical
prostatectomy procedure. • Work plan established up to clinical trial
• Added Value: Needles and bioresorbable wires, potential
reduction of postoperative side effects (impotence,
incontinence or stenosis); safe fast and reliable
safe, PROSPECTS
procedure, adaptable to robotic surgery • Preclinical POC on pig models and device optimization
• CE marking procedure
• French monocentric Clinical trial submission and kick‐off
ACADEMIC/CLINICAL PARTNERS
first,
first then European multicentric clinical trial to obtain
• Pr C. CAROZZO (VetAgroSup Veterinary School, Lyon) reimbursement.
PARTNER COMPANY: Anastom Surgical
• Anastom Surgical will be created in 2012, to develop
and bring UroLink on the market , as well as a portfolio
of circular suturing devices based on the same
technology.
• Contact: Arnold FERLIN (CEO)
( )
Urethra sound Urolink main tool introduced in
sound, Urolink main tool in
urethra to realize anastomosis
32
Maj

33. CLARA – CANCÉROPÔLE LYON AUVERGNE RHÔNE‐ALPES
CLARA’s dynamic network is based on:
CLARA’ d i t ki b d
• 280 Academic Teams
• 80 Clinical Teams
Clinical Teams
• 60 Innovative Enterprises
• 4 University Hospital Centers
• 2 Comprehensive Cancer Centers
• Centers of Excellence: LYRIC, DEVweCAN,
Carnot Institute CALYM…
C t I tit t CALYM
33

35. YOUR CONTACTS AT THE CANCÉROPÔLE CLARA
• Laurent LEVY, Finance and Development Director
• llevy@canceropole‐clara.com
• Ophélie PHILIPOT, Project Manager Transfer
Ophélie PHILIPOT, Project Manager “Transfer”
• ophilipot@canceropole‐clara.com
www.canceropole-clara.com
35

36. ACKNOWLEDGEMENT TO CLARA PROOF OF CONCEPT PARTNERS
Public Authorities
Public Authorities
• European ERDF Funds, INCa, Rhône‐Alpes Region, Rhône Department, Greater Lyon, Isère
Department, Grenoble Metropole, City of Grenoble, Loire Department, Saint‐Etienne Metropole,
Auvergne Region, Puy‐de‐Dôme Department, Clermont Community
Academic and Clinical Centers
• University Hospitals: Lyon Civil Hospitals, Grenoble, Saint‐Étienne, Clermont‐Ferrand
• Cancer Centers: Léon Bérard Cancer Center, Jean Perrin Center
• Research Centers: Lyon Cancer Research Center (CCRL) Alb t B
R hC t L C R h C t (CCRL), Albert Bonniot I tit t NEEL I tit t
i t Institute, NEEL Institute
• Research Institutions: CEA Grenoble, CNRS, École des Mines of Saint‐Étienne, French Blood Institute,
INSA Lyon, INSERM, VetAgroSup
• Universities: Claude Bernard Lyon 1, Joseph Fourier in Grenoble, Pierre Mendès France in Grenoble,
Auvergne University
Auvergne University
Companies
• AAA, ADEPT, Anastom‐Surgical (Créalys incubator), CAVI‐T (Créalys incubator), CEA, CovalAb, EBV‐
Biotech, Ecrins Th
Bi h E i Therapeutics, Edap TMS E d C
i Ed TMS, EndoControl M di l EFS Rhô Al
l Medical, EFS Rhône‐Alpes, ERYtech Ph
ERY h Pharma,
Fluoptics, HLA‐G Technologies, iDD Biotech, ImmunID Technologies, Innate Pharma, Laboratoires
Cyclopharma, Nanobiotix, Nano‐H, Nestis, Netris Pharma, OncoTherapy Sciences, Synthelis
Under the aegis of the Léa and Napoléon Bullukian Foundation
36